Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in mergers and acquisitions (M&A), the transformative power of artificial intelligence (AI), and an evolving investor landscape. With the global biotechnology
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This burgeoning field is set to dramatically enhance the shelf-life and effectiveness of medications, addressing long-standing inefficiencies in traditional drug development. By moving beyond time-consuming, empirical trial-and-error methods, [...]
The pharmaceutical industry is on the cusp of a profound transformation, driven by the synergistic power of artificial intelligence (AI) and digital twins. These cutting-edge technologies are rapidly redefining the landscape of drug discovery and development, promising to dramatically cut down timelines, reduce costs, and enhance the precision with which life-saving medicines are brought to [...]
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance, particularly by companies at the forefront of artificial intelligence (AI), tech stocks are now experiencing a noticeable downturn. This
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 20, 2025, at 9:30 a.m. ET / 2:30 p.m. GMT.
Washington D.C. – November 12, 2025 – Looking back from today, the critical period following a hypothetical, yet highly plausible, U.S. government shutdown in late 2024 served as a stark reminder of the indispensable role of timely economic data. As federal agencies grappled with reopening, the U.S. Labor Department
The Nasdaq Composite (NASDAQ: IXIC) experienced back-to-back losses on November 11 and 12, 2025, signaling a significant recalibration in the financial markets. This downturn, primarily driven by growing concerns over stretched valuations in the artificial intelligence (AI) sector and a pronounced rotation of capital into more traditional industries, marks a
New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) has shattered previous records, closing at an all-time high of 48,254.82 today, marking a significant milestone for the venerable index. This historic surge, following another record close yesterday, injects a palpable sense of optimism into the
The financial markets are currently exhibiting an extraordinary and complex phenomenon: both traditional safe-haven assets, gold and silver, are experiencing robust rallies, while the Dow Jones Industrial Average (DJIA) has simultaneously surged past the 48,000-point mark. As of November 12, 2025, gold prices are trading around $4,105-$4,
New York, NY – November 12, 2025 – In a remarkable display of market resilience and underlying tension, the Dow Jones Industrial Average (DJIA) has surged past the 48,000-point threshold, closing at an unprecedented 48,015.79. This historic equity rally is unfolding concurrently with a robust ascent in precious metals,
The Dow Jones Industrial Average (DJIA) made history on Wednesday, November 12, 2025, surging past the 48,000-point mark for the first time ever, gaining nearly 380 points. This significant rally was fueled by a wave of optimism surrounding the imminent resolution of a protracted U.S. government shutdown, which
